Data as of Dec 24
| +0.77 / +4.79%|
Xencor, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company uses proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. It focuses on the portion of the antibody that interacts with multiple segments of the immune system, referred to as the Fc domain, which is constant and interchangeable among antibodies. Xencor was founded Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
|Bassil I. Dahiyat||President, Chief Executive Officer & Director|
|John J. Kuch||Vice President-Finance|
|John R. Desjarlais||Chief Scientific Officer & Senior VP-Research|
|Paul A. Foster||Chief Medical Officer|
|Lloyd A. Rowland||Chief Compliance Officer, SVP & General Counsel|